Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy
- Author:
Min Kyu KIM
1
;
Sang Eok LEE
;
Jang Sihn SOHN
;
In Seok CHOI
;
Ju Ik MOON
;
Dae Sung YOON
;
Ki Won CHUN
;
Hye Yoon LEE
;
Nak Song SUNG
;
Si Min PARK
;
Won Jun CHOI
Author Information
- Publication Type:Original Article
- Keywords: HER-2; Gastric cancer
- MeSH: Classification; Epidermal Growth Factor; Gastrectomy; Humans; Receptor, Epidermal Growth Factor; Recurrence; Stomach Neoplasms
- From: Korean Journal of Clinical Oncology 2017;13(1):25-31
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study aimed to clarify the association between human epidermal growth factor receptor 2 (HER-2) status and the clinicopathologic factors of patients who underwent curative intent gastrectomy.METHODS: From June 2011 to May 2015, curative intent gastrectomy was performed in 441 patients at Konyang University Hospital. Among them, we evaluated the HER-2 status in 113 patients. Data on clinicopathologic parameters such as age, sex, histological subtype, endoscopic Lauren classification, tumor location, size, presence of lymphovascular invasion, invasion depth, pathologic stage, HER-2 overexpression, recurrence and survival were obtained. In this study, pathological HER-2 intensity scores of 0, 1+, and 2+ were assumed to be negative, 3+ only was to be positive for overexpression.RESULTS: In a total of 113 cases who underwent curative intent gastrectomy with HER-2 testing, 16 (14.2%) cases had positivity of HER-2 overexpression. HER-2 overexpression had significant associations with tumor stage (19.0% in I-IIIb vs. 2.9% in IIIc-IV, P=0.036). Survival analysis of HER2 overexpression has no significant difference.CONCLUSION: In this study, HER-2 overexpression rate was 14.2% and patient tumor stage had significant association with HER-2 overexpression.
